Although the Company does not have any specific merger, stock exchange, asset acquisition, reorganization or other business combination under consideration or contemplation, the Company intends to capitalize on the significant strength of its management team, which is experienced in sourcing, structuring, financing and consummating business combinations in a variety of industry sectors. The Company believes that it has extensive contacts and sources, ranging from public and private company contacts, private equity funds, and investment bankers to attorneys, accountants and business brokers, from which to generate acquisition opportunities. The Company further believes that its extensive contacts, relationships and sources, when combined with the skills of its management team will help it identify and structure attractive acquisition opportunities for its stockholders. Biographical information about the Company's current management team follows.
Robert Baron was initially appointed to our board July 10, 2006. Mr. Baron presently serves as a member of the board of directors of three publicly-traded companies, OPKO Health, Inc. (f/k/a eXegenics, Inc.), Hemobiotech, Inc., and Andover Medical, Inc. OPKO Health was a public shell that in March 2007 completed a three-way merger with Froptix Corporation and Acuity Pharmaceuticals, Inc. OPKO Health is engaged in the development of therapies for the treatment and prevention of ophthalmic disease. Hemobiotech is a development stage biotechnology company and Andover Medical a durable medical equipment company.
Robert Coutu was elected to our board on July 17, 2007 and presently
serves as the president
|SOURCE NanoSensors, Inc.|
Copyright©2007 PR Newswire.
All rights reserved